Bristol Myers Squibb (BMY) is considered undervalued, trading at a forward P/E of 9.8x with a 3.7% dividend yield. Its growth portfolio now accounts for nearly 60% of revenue, helping offset declines in legacy drugs and supporting 5% year-over-year revenue growth. Management has raised the full-year adjusted EPS guidance, driven by strong performance of the drug Eliquis and a pipeline of over 10 potential new medicines. Despite the downgrade from 'Strong Buy' to 'Buy' due to valuation concerns, BMY remains attractive for income, growth, and safety margins.
RBC Capital Markets reaffirmed its 'outperform' rating on Oxford BioMedica, despite clinical trial pauses by partners Novartis and BMS. The broker views the trial halts as having limited financial impact, with only £10-16 million in annual clinical r...
The Health Care Select Sector SPDR Fund (XLV) offers broad healthcare exposure but delivers a low dividend yield around 1.5% due to its cap-weighted structure favoring large, lower-yield stocks like Eli Lilly. Directly owning top XLV holdings AbbVie,...
